Ozempic and Wegovy have become some of the most talked-about medications in the world, largely because of their ability to help people lose weight and control blood sugar.
But scientists are increasingly interested in whether these drugs could have effects beyond diabetes and weight management.
Now, a major study involving more than 70,000 Americans has uncovered a potentially important connection between GLP-1 medications and psychiatric health.
Researchers found that people living with both schizophrenia and type 2 diabetes who started taking these medications were significantly less likely to require emergency psychiatric care than those who did not.
Also read: Menopause before 40 may carry a hidden heart risk
According to the study published in The Lancet Psychiatry on October 14, 2026, patients who started GLP-1 treatment had a 24 percent lower relative risk of psychiatric hospitalization and a 29 percent lower relative risk of visiting an emergency department for a mental health crisis.
The findings suggest that medications developed to treat physical health conditions could potentially have additional benefits for people living with serious mental illness.
However, scientists caution that the results do not prove these drugs directly improve schizophrenia symptoms.
More than 70,000 patients were included in the research
The international research team examined electronic medical records from 70,257 adults in the United States who had been diagnosed with both schizophrenia and type 2 diabetes.
Also read: Scientists may have found why food still tastes different years after COVID
Schizophrenia is a serious mental health condition that can affect how people think, perceive reality and experience emotions. Some patients experience hallucinations or delusions, while others struggle with motivation, concentration and everyday activities.
Managing the condition often requires long-term treatment with antipsychotic medication. However, some of these medications can cause significant weight gain, increase appetite and make blood sugar more difficult to control.
This creates an additional challenge because people with schizophrenia already face a higher risk of developing diabetes and cardiovascular disease.
To investigate whether diabetes medications might make a difference, researchers compared patients who started GLP-1-based treatment with those who started other types of diabetes medication or did not begin any of the drug treatments being studied.
Also read: Some carry Alzheimer's riskiest gene and never get it: a rare mutation may finally explain why
Of the participants, 9,093 started a GLP-1 medication, while the remaining patients belonged to comparison groups receiving different treatment approaches.
The researchers examined records covering treatment decisions from January 2018 to October 2025, with follow-up extending into March 2026.
The difference in psychiatric hospitalizations was striking
When researchers compared the groups, they found that patients starting GLP-1 medications had a lower risk of experiencing a psychiatric crisis serious enough to require hospital treatment.
Compared with people who did not start any of the diabetes medications being examined, GLP-1 users had a 24 percent lower adjusted risk of psychiatric hospitalization.
Also read: Nearly eight years on daily opioids didn't ease chronic back pain, and something else got worse
They also had a 29 percent lower adjusted risk of attending an emergency department for psychiatric reasons.
The pattern remained when researchers compared GLP-1 users with people receiving other common diabetes medications.
The risk of psychiatric hospitalization was 18 percent lower than among patients starting DPP-4 inhibitors and 17 percent lower than among those starting SGLT2 inhibitors.
These are two established types of medication used to help manage blood sugar in people with type 2 diabetes.
Also read: An extra piece of fruit a day may quietly shape your teenager's mental health
The fact that the association remained when GLP-1 drugs were compared with other active diabetes treatments made the findings particularly interesting.
However, the percentages represent relative differences in adjusted risk, not percentage-point reductions or guarantees that an individual patient will avoid hospitalization.
Not all GLP-1 medications showed the same results
The researchers also examined whether the findings differed depending on which medication patients received.
Several well-known drugs showed an association with lower psychiatric hospitalization risk.
These included semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, and tirzepatide, which is sold under the brand names Mounjaro and Zepbound.
Tirzepatide works on two hormone pathways, GIP and GLP-1, while semaglutide targets the GLP-1 receptor.
Liraglutide, another medication used to manage diabetes and weight, was also associated with lower psychiatric care needs.
However, the researchers did not find the same clear association with dulaglutide.
This difference suggests that the findings should not automatically be applied to every medication in the broader GLP-1 treatment category.
It also raises questions about whether certain drugs have different effects, although the study was not designed to determine why those differences occurred.
The benefits may not be explained by weight loss alone
One of the study's most intriguing findings involved patients' weight.
Because GLP-1 medications are known for reducing appetite and helping people lose weight, researchers wanted to understand whether the lower psychiatric risk was simply connected to weight reduction.
The association was strongest among people who lost weight, but it also appeared in some comparisons involving patients whose weight remained stable.
Results were less consistent among patients who gained weight, meaning the findings do not establish that the association is independent of weight loss.
Nevertheless, the researchers believe the results raise an important question about whether these medications might have benefits beyond improving metabolism.
Scientists have previously investigated how GLP-1 medications influence brain systems involved in appetite and reward. However, there is not yet sufficient evidence to conclude that these effects directly improve schizophrenia.
Another possible explanation involves the relationship between physical health and psychiatric treatment.
Experts believe the drugs could help patients stay on treatment
Some antipsychotic medications can increase hunger so dramatically that managing body weight becomes extremely difficult.
For patients who experience these side effects, the frustration can sometimes contribute to stopping medication, which can increase the risk of psychiatric relapse.
Professor Joseph Firth, a specialist in psychology and mental health at the University of Manchester, discussed this possibility in comments published by the UK Science Media Centre.
He explained that GLP-1 medications can strongly affect appetite and feelings of fullness, potentially helping counteract some of the metabolic side effects associated with antipsychotic treatment.
If patients find it easier to manage their weight and physical health, they may also find it easier to continue taking essential psychiatric medication.
That could potentially reduce the risk of relapse and hospitalization without the GLP-1 medication having any direct effect on the underlying mental illness.
However, this remains a possible explanation rather than a demonstrated mechanism.
Other experts have also pointed out that patients prescribed GLP-1 medications may receive more regular medical attention, have better health insurance or be more actively involved in managing their health.
Those differences could influence hospitalization rates even if the medications themselves provide no direct psychiatric benefit.
A Danish clinical trial found a more complicated picture
The latest findings become even more interesting when compared with earlier research involving patients with schizophrenia.
In September 2025, a randomized clinical trial published in JAMA Psychiatry examined whether semaglutide could improve metabolic health among people receiving antipsychotic medication.
The Danish trial involved 154 patients with schizophrenia, overweight or obesity, and prediabetes.
Participants received either semaglutide or a placebo for 30 weeks, allowing researchers to compare the effects of the medication under controlled conditions.
The results showed significant improvements in physical health.
Patients receiving semaglutide lost approximately 9.2 kilograms more than those receiving placebo, while their average blood sugar measurements also improved.
Importantly, researchers did not observe a significant worsening of psychiatric symptoms.
But they also did not find a statistically significant improvement in schizophrenia symptoms or mental quality-of-life scores.
The findings suggest that semaglutide can improve important aspects of physical health in this patient population without necessarily treating the psychiatric condition itself.
This distinction is particularly important when interpreting the much larger American study.
Why researchers are urging caution
Despite the encouraging results, the new study has an important limitation: it was observational.
Instead of randomly assigning patients to different treatments, researchers examined medical records to identify patterns among people who had already received certain medications.
The researchers used statistical methods to account for differences in age, health conditions and medication use, but they could not eliminate every possible explanation for the findings.
For example, patients who receive GLP-1 medications might have better access to healthcare or more stable psychiatric symptoms before starting treatment.
Dr. Sameer Jauhar, a psychiatrist and researcher at Imperial College London, noted that the lower hospitalization rates appeared very soon after treatment began.
He suggested that this could indicate differences between the patients themselves rather than a direct effect of the medication, which might be expected to develop over a longer period.
Other independent experts agreed that the research was promising but emphasized that randomized clinical trials are necessary before drawing conclusions about psychiatric benefits.
The central question remains unanswered: Do GLP-1 medications actually reduce psychiatric symptoms and prevent relapses, or are the findings explained by differences in patients' physical health and healthcare?
What this means for people taking antipsychotic medication
For people living with schizophrenia and type 2 diabetes, the research highlights the importance of treating physical and mental health together.
Diabetes, obesity and cardiovascular disease can create serious long-term health complications, and the metabolic side effects of antipsychotic medications may make those risks harder to manage.
GLP-1 medications are already established treatments for type 2 diabetes, and some are approved for weight management in appropriate patients.
The latest findings suggest there may be additional advantages worth investigating when these medications are prescribed for existing medical reasons.
However, they are not approved treatments for schizophrenia, and doctors should not prescribe them solely to prevent psychiatric hospitalizations based on this study.
Patients should also avoid changing or stopping antipsychotic medication without medical advice. Effective psychiatric treatment remains essential, regardless of which diabetes medication someone receives.
Anyone concerned about weight gain, blood sugar or other side effects associated with antipsychotic treatment can discuss the available options with their healthcare professional.
For researchers, the next step is to establish whether the association identified in this study can be reproduced in randomized trials.
If future studies confirm a genuine benefit, GLP-1 medications could eventually play a broader role in healthcare for people living with serious mental illness.
For now, the discovery offers an encouraging possibility, but not proof that drugs such as Ozempic can treat schizophrenia.
This article is made and published by Aksel Kryhlmand, who may have used AI in the preparation.